Biography and Research Information
OverviewAI-generated summary
Nyosha Moore conducts research focused on mutagenicity and genotoxicity, particularly investigating N-nitrosamine compounds. Her work involves optimizing detection methods for these substances using in vitro assays, such as the Ames test, which is employed to assess bacterial mutagenicity. Moore has published on the mutagenicity and genotoxicity of N-nitroso propranolol in both bacterial and human cell systems. Her research has involved collaboration with several colleagues at the National Center for Toxicological Research, including Nan Mei, Roberta A. Mittelstaedt, Robert H. Heflich, and S A Montoya Guerrero, with whom she shares multiple publications. Moore's scholarly output includes a h-index of 2 and a total of 60 citations across her 2 publications.
Metrics
- h-index: 2
- Publications: 2
- Citations: 63
Selected Publications
-
Optimizing the detection of N-nitrosamine mutagenicity in the Ames test (2024)
-
Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays (2023)
Collaboration Network
Top Collaborators
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Optimizing the detection of N-nitrosamine mutagenicity in the Ames test
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Optimizing the detection of N-nitrosamine mutagenicity in the Ames test
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Optimizing the detection of N-nitrosamine mutagenicity in the Ames test
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Optimizing the detection of N-nitrosamine mutagenicity in the Ames test
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Optimizing the detection of N-nitrosamine mutagenicity in the Ames test
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Optimizing the detection of N-nitrosamine mutagenicity in the Ames test
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Optimizing the detection of N-nitrosamine mutagenicity in the Ames test
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Optimizing the detection of N-nitrosamine mutagenicity in the Ames test
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Optimizing the detection of N-nitrosamine mutagenicity in the Ames test
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Optimizing the detection of N-nitrosamine mutagenicity in the Ames test
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
Similar Researchers
Based on overlapping research topics